A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Active:	No
Cancer Type:	Kidney Cancer Unknown Primary	NCT ID:	NCT04586231
Trial Phases:	Phase III	Protocol IDs:	6482-011 (primary) MK-6482-011 NCI-2020-11420 2020-002075-35
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT04586231

Summary

This study will compare the efficacy and safety of belzutifan + lenvatinib versus
cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell
component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in
terms of progression-free survival or overall survival.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.